Previous 10 | Next 10 |
Phase 2 trial of Amgen’s investigational KRAS G12C inhibitor, sotorasib, demonstrated comparable efficacy between patients identified as KRAS G12C positive using Guardant360 CDx liquid biopsy or tissue biopsy Guardant Health, Inc. (Nasdaq: GH), along with lead...
Shares of Guardant Health (NASDAQ: GH) were rising 4.7% higher as of 10:54 a.m. EDT on Thursday. The gain came after the company announced that its Guardant Reveal blood test received Clinical Laboratory Evaluation Program (CLEP) approval from the New York State Department of Health...
Guardant Health (GH) announces that the New York State Department of Health Clinical Laboratory Evaluation Program ((CLEP)) has approved the Guardant Reveal liquid biopsy test for the detection and monitoring of minimal residual disease ((MRD)) in patients with early-stage cancer (stage II an...
Guardant Health, Inc. (Nasdaq: GH) announced that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the Guardant Reveal™ liquid biopsy test for the detection and monitoring of minimal residual disease (MRD) in patients with early-s...
The challenge by the U.S. Federal Trade Commission to block the proposed acquisition of Grail by Illumina ([[ILMN]] +4.0%) led to a ~6.6% sell-off of the stock yesterday.Citing a brighter post-COVID future for the company, Canaccord Genuity has upgraded the stock to buy from hold with the pri...
Guardant Health, Inc. (Nasdaq: GH) announced that the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for the Guardant360 ® CDx test. The Guardant360 CDx test is the first FDA-approved liquid biopsy for comprehen...
Consistent with studies, across various treatments and indications, 1-9 showing Guardant Health blood test provides early indication of treatment response and clinical outcomes For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable ...
Guardant Health (NASDAQ: GH) has experienced some big swings both up and down with its share price in recent months. However, there's a more important thing to focus on with this stock than its volatility. In this Motley Fool Live video recorded on March 17, 2021 , Motley Fo...
Guardant Health is a company that develops liquid biopsy technology to improve how we diagnose, screen for, and treat cancer. The company's robust product pipeline should expand its TAM and fuel long-term growth. The stock is quite expensive, and with guided revenue growth at less...
Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...